GORE® CARDIOFORM Septal Occluder
DESIGNED TO CONFORM.
SO THE HEART DOESN’T HAVE TO.
The GORE® CARDIOFORM Septal Occluder advances PFO closure with a solution designed to naturally conform to a patient’s unique PFO anatomy — delivering on long-term safety and performance.*,1
The GORE® CARDIOFORM Septal Occluder is a permanently implanted device indicated for the percutaneous, transcatheter closure of atrial septal defects (ASDs), such as ostium secundum and patent foramen ovale.
Advanced materials delivering exceptional conformability†,‡,§,II,1-3
More than 60 years of world-leading materials science expertise has resulted in a solution that is designed to naturally conform across a broad range of PFO anatomies to treat simple and complex defects.II,1-3
Watch how the GORE® CARDIOFORM Septal Occluder is implanted.
Long-term safety and performance
After over a decade of clinical use and 68,000+ devices sold globally, the extended 5-year follow-up results from the REDUCE Study highlight that GORE® CARDIOFORM Septal Occluder can be trusted for long-term safety and performance.*,IIII,1
Reliable and safe delivery
With straightforward procedural steps, the GORE® CARDIOFORM Septal Occluder delivery system allows for repositioning and retrieval¶¶, facilitating reliable and accurate deployment across PFO anatomies.*
1 Deploy¶¶
Handle design with slider enables accurate deployment with the ability to reposition.
2 Lock¶¶
Simple-to-use locking mechanism. Occluder is partially released and remains tethered to delivery system.
3 Release¶¶
Pull the retrieval cord until completely removed to release the device from the delivery system.
Device specifications
With the conformable design of the GORE® CARDIOFORM Septal Occluder, three devices cover PFOs and ASDs up to 17 mm.¶¶
| Labeled Occluder diameter | Maximum recommended defect size measured with stop flow balloon sizing | Catheter size without guidewire*** |
|---|---|---|
| 20 mm | 11 mm | 10 Fr |
| 25 mm | 14 mm | 10 Fr |
| 30 mm | 17 mm | 10 Fr |
Understanding PFO
For patients and caregivers interested in learning more about PFO-related stroke and PFO closure.
This video was produced for W. L. Gore & Associates by BBC StoryWorks, the commercial content division of BBC Global News.
Life after stroke: Kathryn’s story
Are you young and healthy, but have had a stroke? You are not alone. Kathryn recalls the early, nerve-racking days after her stroke and diagnosis. Learn more about her journey, her decision to close her PFO and life after stroke.
* All PFO anatomies within indicated sizing parameters of the Instructions for Use.
† 99% effective closure rate across PFO anatomies at 24 months.
‡ Effective closure defined as freedom from large shunt > 25 bubbles as detected by transthoracic echocardiography adjudicated by Echo Core Lab.
§ Data on file 2020; W. L. Gore & Associates, Inc.; Flagstaff, AZ.
II All PFO anatomies were eligible for inclusion into this study within indicated sizing parameters of the Instructions for Use.
¶ Nickel titanium
** Patients allergic to nickel may suffer an allergic reaction to the GORE® CARDIOFORM Septal Occluder device. Certain allergic reactions can be serious; patients should be instructed to notify their physicians immediately if they suspect they are experiencing an allergic reaction such as difficulty in breathing or inflammation of the face or throat. Some patients may also develop an allergy to nickel if this device is implanted. Refer to the Instructions for Use for complete device information, including contraindications, warnings and cautions.
†† As characterized by an in vitro assessment.
‡‡ Reported incidence rate of device-related cardiac erosions for GORE® CARDIOFORM Septal Occluder and
GORE® CARDIOFORM ASD Occluder. Data from CATSWeb Product Surveillance Tracking System (PSTS). June, 2011-August, 2022.
§§ In patients with a PFO and history of cryptogenic stroke.
IIII The REDUCE Study determined safety and efficacy of PFO closure with the GORE® CARDIOFORM Septal Occluder or GORE® HELEX® Septal Occluder plus antiplatelet medical management compared to antiplatelet medical management alone in patients with a PFO and history of cryptogenic stroke. All PFO anatomies were eligible for inclusion into this study within indicated sizing parameters of the Instructions for Use.
¶¶ Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for markets where this product is available. RXOnly
*** Recommendation for sheath size is 2 Fr larger when used with a wire.
- Kasner SE, Rhodes JF, Andersen G; Gore REDUCE Clinical Study Investigators. Five-year outcomes of PFO closure or antiplatelet therapy for cryptogenic stroke. New England Journal of Medicine 2021;384(10):970-971.
- Lefebvre B, Naidu S, Nathan AS, et al. Impact of echocardiographic parameters on recurrent stroke in the randomized REDUCE PFO cryptogenic stroke trial. Structural Heart 2021;5(4):367-375.
- Søndergaard L, Kasner SE, Rhodes JF, et al.; Gore REDUCE Study Investigators. PFO closure or antiplatelet therapy for cryptogenic stroke. New England Journal of Medicine 2017;377(11):1033-1042.
- Verma DR, Khan MF, Tandar A, et al. Nickel elution properties of contemporary interatrial shunt closure devices. Hours of Invasive Cardiology 2015;27: 99-104.
Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly
Products listed may not be available in all markets.
In some jurisdictions, ASPIRIN is a trademark of Bayer Intellectual Property GmbH or its affiliated companies.
ABBOTT and AMPLATZER are trademarks of Abbott Laboratories.
GORE, Together, improving life, CARDIOFORM, HELEX and designs are trademarks of W. L. Gore & Associates.
23902800-EN